
    
      This study is designed to evaluate the safety, tolerability, pharmacokinetics and
      pharmacodynamics of ATI-50002 Topical Solution in patients with Alopecia Universalis and
      Alopecia Totalis. Concentrations of ATI-50002 in the blood and skin will be assessed after 28
      days of treatment with ATI-50002 Topical Solution.
    
  